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Abstract 64 
Background: Up to 7% of all adrenal incidentalomas (AIs) are pheochromocytomas (PCCs). In 65 
the evaluation of AI, it is generally recommended to exclude PCC by measurement plasma free or 66 
24h urinary fractionated metanephrines. However, recent studies suggest to abstain from 67 
biochemical exclusion of PCC in cases of lesions with computed tomography (CT) characteristics 68 
of an adrenocortical adenoma (ACA).                   69 
Aim: To determine the prevalence of PCCs with ACA-like attenuation or contrast washout on CT.  70 
Methods: For this multicenter retrospective study, two central investigators independently 71 
analyzed the CT reports of 533 patients with 548 histologically confirmed PCCs. Data on tumor 72 
size, unenhanced Hounsfield Units (HU), absolute percentage washout (APW) and relative 73 
percentage washout (RPW) were collected besides clinical parameters.  74 
Results: Among the 376 PCCs for which unenhanced attenuation data were available, 374 had an 75 
attenuation of >10 HU (99.5%). In the two exceptions (0,5%), unenhanced attenuation was 76 
exactly 10 HU, which lies just within the range of ≤10 HU that would suggest a diagnosis of ACA. 77 
Of 76 PCCs with unenhanced HU >10 and available washout data, 22 (28,9%) had a high APW 78 
and/or RPW, suggestive of ACA.  79 
Conclusion: Based on the lack of PCCs with an unenhanced attenuation of <10 HU, and the low 80 
proportion (0,5%) of PCCs with an attenuation of =10 HU, it seems reasonable to abstain from 81 
biochemical testing for PCC in AIs with an unenhanced attenuation ≤10 HU. The assessment of 82 
contrast washout, however, is unreliable to rule out PCC.    83 
Précis: This retrospective study examines the CT characteristics of 548 pheochromocytomas 84 
(PCCs). The findings suggest to avoid biochemical testing for PCC in incidentalomas with 85 
unenhanced attenuation ≤10HU. 86 
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Introduction 90 
Adrenal pheochromocytomas (PCCs) and extra-adrenal sympathetic paragangliomas are rare 91 
tumors that arise from catecholamine producing chromaffin cells 1. Up to 40% of chromaffin 92 
tumors are associated with hereditable tumor syndromes 2-5. The most accurate diagnostic test 93 
for the biochemical diagnosis of these tumors is the measurement of plasma free or 24h urinary 94 
fractionated metanephrines 6,7. Typical symptoms and signs include headache, tremors, 95 
palpitations, sweating, and anxiety. However, in up to 25% of patients signs and symptoms are 96 
lacking and up to 30% of PCCs are diagnosed following the discovery of an adrenal 97 
incidentaloma (AI) 7,8. 98 
The prevalence of AI on thoracic, abdominal and pelvic computed tomography (CT) ranges 99 
between 1.0% and 8.7% depending on age 9-14. The majority of AIs are adrenocortical adenoma 100 
(ACA) 12. Less prevalent causes are myelolipomas, cysts, adrenocortical carcinoma and 101 
metastases from other malignancies. PCCs account for up to 7% of AIs 7. In contrast to situations 102 
when significant adrenal hormone secretion or malignancy are suspected, no treatment is 103 
indicated for benign non-functioning ACA. In 2016, the European Society of Endocrinology (ESE) 104 
in collaboration with the European Network for the Study of Adrenal Tumors (ENSAT) published 105 
a guideline to provide clinicians with evidence-based recommendations for clinical management 106 
of patients with AIs 7. This guideline adapts a generally accepted approach in the evaluation of AI 107 
by taking into account quantitative CT characteristics. Either an attenuation of ≤10 Hounsfield 108 
Units (HU) on an unenhanced CT, or an absolute percentage washout (APW) ≥60% or a relative 109 
percentage washout (RPW) ≥40% on a CT with delayed washout after 10-15 min are considered 110 
suggestive of ACA. However, the guidelines and an accompanied meta-analysis 15 clearly 111 
indicated that the unenhanced CT is the only reliable method to differentiate benign from 112 
malignant adrenal tumors. In addition, it was recommended to perform an endocrine work-up 113 
for AI, including the measurement of plasma free or 24h urinary fractionated metanephrines. 114 
However, it was also discussed that it could be reasonable to avoid biochemical testing for PCC 115 
in patients AI with a unenhanced attenuation of ≤10 HU. Nevertheless, the authors 116 
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acknowledged that only two small studies were published on this topic 16,17. The findings in the 117 
latter studies require confirmation in a larger number of patients before substantiated 118 
statements can be made. It is important to note that PCCs demonstrating an attenuation ≤10 HU 119 
have been described in literature, though very uncommonly 18,19. Hence, in this international 120 
multicenter study we retrospectively evaluated the quantitative CT characteristics of PCCs, as 121 
indicated in the radiological reports, to assess the prevalence and associated characteristics of 122 
PCCs with an ACA-like attenuation on CT scan, taking into account both unenhanced attenuation 123 
and contrast washout measurements.  124 
 125 
Methods 126 
Patients 127 
We included patients with a histologically proven PCC (single or multiple) who had undergone a 128 
pre-operative CT scan, i.e. either unenhanced CT (+/- contrast enhanced CT) or contrast washout 129 
CT. Patients with post-contrast CT scan only were not eligible for inclusion. Patients had been 130 
diagnosed and treated in centers affiliated to ENSAT. Participating ENSAT centers were Mayo 131 
Clinic (n=153), Rochester, USA; Radboud University Medical Center, Nijmegen, The Netherlands 132 
(n=46); University Hospital Center Zagreb, Zagreb, Croatia (n=43); Carol Davila University of 133 
Medicine and Pharmacy, Bucharest, Romania (n=42); Medical University of Warsaw, Warsaw, 134 
Poland (n=33); CHU de Bordeaux, Pessac, France (n=29); University Medical Center Groningen, 135 
Groningen, The Netherlands (n=21); University Hospital of Florence, Florence, Italy (n=21); 136 
University of Birmingham, Birmingham, United Kingdom (n=20); Center hospitalier de 137 
l'Université de Montréal, Montreal, Canada (n=19); Hospices Civils de Lyon, Lyon, France 138 
(n=17); University Hospital of Wuerzburg, Wuerzburg, Germany (n=17); University Hospital of 139 
Krakow, Krakow, Poland (n=16); Cambridge University Hospitals, Cambridge, United Kingdom 140 
(n=12); Endocrinology in Charlottenburg, Berlin, Germany (n=12); Center Hospitalier  141 
Universitaire de Liege, Liege, Belgium (n=10); Medizinische Klinik und Poliklinik IV Ludwig-142 
Maximilians-Universität München, Munich, Germany (n=10); Hospital General Universitario de 143 
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Albacete, Albacete, Spain (n=5). Patients provided informed consent, either under ENSAT or 144 
local institutional protocol, when required. Two hundred fourteen patients from the two Dutch 145 
centers were also included in a previous study on this topic by Buitenwerf et al.20. In the latter 146 
study, a central re-evaluation of CT images was performed to calculate unenhanced attenuation, 147 
whereas in the current study, both unenhanced attenuation and contrast washout were analyzed 148 
based on locally generated CT reports. Additional inclusion criteria were age at diagnosis >18 149 
years, a diagnosis in or after the year 2000, availability of the CT report and clinical annotations 150 
(age, sex, underlying hereditary syndrome).  151 
 152 
Biochemical testing and imaging 153 
Biochemical testing, usually by measurement of plasma free or 24h urinary fractionated 154 
metanephrines, was performed according to local protocols with corresponding reference 155 
values. If metanephrines were not available, 24h urine or plasma catecholamines were utilized, 156 
in order of preference. Biochemical phenotypes were categorized as “adrenergic”, 157 
“noradrenergic” or “normal”. The phenotype was classified as “adrenergic” when the increment 158 
of metanephrines, relative to the upper limits of normal, exceeded 5% of the combined 159 
metanephrine and normetanephrine increments. Patients in whom these criteria were not 160 
fulfilled and in whom normetanephrine levels exceeded the upper limits of normal were 161 
classified as “noradrenergic” 21. In addition, CT scans were performed according to local 162 
protocols regarding contrast procedure, acquisition and reconstruction parameters and 163 
approach to draw the region of interest for HU measurements. Unenhanced, unenhanced and 164 
contrast and dedicated adrenal CT scan were included. Dedicated adrenal CT scan requires 165 
attenuation measurements before contrast administration, 60s and 10-15 min after contrast 166 
injection. 167 
 168 
Evaluation of CT reports 169 
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Anonymized imaging reports of pre-operative CT scans, generated by local radiologists as part of 170 
routine diagnostic evaluation, were submitted for central analysis. The reports were evaluated 171 
and scored independently by two observers (LC; JVH) who were blinded to the clinical 172 
information. Type of CT scan and field of view, number and location of lesions, tumor size, 173 
unenhanced HU, APW and RPW were considered. In case multiple unenhanced HU values were 174 
mentioned, the highest value was chosen for analysis. When in the local report values for 175 
APW/RPW were not mentioned, APW and RPW were calculated according to the formulas 176 
below, provided that the required parameters were available. 177 
APW =
𝐻𝑈 𝑝𝑜𝑟𝑡𝑎𝑙 𝑣𝑒𝑛𝑜𝑢𝑠 𝑝ℎ𝑎𝑠𝑒 − 𝐻𝑈 𝑑𝑒𝑙𝑎𝑦𝑒𝑑 𝑝ℎ𝑎𝑠𝑒
𝐻𝑈 𝑝𝑜𝑟𝑡𝑎𝑙 𝑣𝑒𝑛𝑜𝑢𝑠 𝑝ℎ𝑎𝑠𝑒 − 𝐻𝑈 𝑢𝑛𝑒𝑛ℎ𝑎𝑛𝑐𝑒𝑑 
 𝑥 100% 178 
RPW =
𝐻𝑈 𝑝𝑜𝑟𝑡𝑎𝑙 𝑣𝑒𝑛𝑜𝑢𝑠 𝑝ℎ𝑎𝑠𝑒 − 𝐻𝑈 𝑑𝑒𝑙𝑎𝑦𝑒𝑑 𝑝ℎ𝑎𝑠𝑒
𝐻𝑈 𝑝𝑜𝑟𝑡𝑎𝑙 𝑣𝑒𝑛𝑜𝑢𝑠 𝑝ℎ𝑎𝑠𝑒
 𝑥 100% 179 
PCCs were classified as ACA-like based on quantitative CT characteristics in case one of the 180 
following criteria were fulfilled: 1. Attenuation on unenhanced CT <10 HU or 2. Attenuation on 181 
unenhanced CT >10 HU and APW ≥60% and/or RPW ≥40%.  182 
 183 
Data management and statistical analysis 184 
Statistical analysis was performed with SPSS 17.0 for Windows. Clinical characteristics were 185 
compared between PCC patients with and without an ACA-like attenuation based on quantitative 186 
criteria. Characteristics were compared using an unpaired T test if variables were continuous or 187 
a Chi square test if variables were categorical. A two-sided P value of <0.05 was considered 188 
statistically significant.   189 
 190 
Results 191 
In total, 1011 cases of PCCs and extra adrenal sympathetic paragangliomas were screened for 192 
eligibility by the local investigators at the 18 participating centers. Four hundred and seven 193 
cases were excluded, mainly because of the performance of post-contrast CT only (n=305). After 194 
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central review, 71 additional cases were excluded based on a diagnosis of extra-adrenal 195 
paraganglioma rather than PCC (n=25), lack of CT report (n=21), incomplete CT report (n=14), 196 
age <18 years (n=5), lack of histological proof of PCC (n=4) and performance of post-contrast CT 197 
only (n=2). Out of the remaining 533 patients with 548 histologically confirmed PCCs, 198 
quantitative CT characteristics were available in 368 patients with 382 PCCs (376 unenhanced 199 
HU +/- washout and 6 washout only). The clinical characteristics are given in Table 1. Details on 200 
CT scan protocols and availability of quantitative data from radiology reports are given in Table 201 
2. 202 
 203 
PCCs with ACA-like attenuation or washout  204 
Among the 376 PCCs for which unenhanced attenuation was available, 374 had an attenuation of 205 
>10 HU (99.5%, Figure 1). In the two exceptions (0,5%), unenhanced attenuation was exactly 10 206 
HU, which lies just within the range of ≤10 HU that would suggest a diagnosis of ACA 207 
(supplemental Table 1 22). Of these two PCCs, the histology reports were re-evaluated. The first 208 
lesion was a PCC with extensive central haemorrhage. The second adrenal contained areas of 209 
prominent nodular adrenocortical hyperplasia besides PCC.  210 
Of 76 PCCs with unenhanced HU >10 and available washout, 22 (28,9%) had an APW ≥60% 211 
and/or an RPW ≥40%, suggestive of ACA. In one additional PCC APW/RPW was high as well, but 212 
unenhanced attenuation was unavailable. The local radiologists reported on six additional 213 
lesions with characteristics of ACA. The reasons for this, however, could not be verified, since 214 
washout data were unavailable and in the two cases where unenhanced attenuation was 215 
mentioned, it was >10 HU.  216 
The PCCs with an unenhanced attenuation of >10 HU and high APW and/or RPW (n=22) did not 217 
differ from those with an unenhanced attenuation of >10 HU and low washout (n=54) with 218 
respect to sex, tumor size and hereditary syndrome (data not shown). 219 
Two hundred eighty-two out of 548 PCCs (51.4%) were initially discovered as AI in 276 patients. 220 
One out of 199 lesions with available quantitative was data was among the two lesions of 10 HU. 221 
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In this subgroup, out of 29 PCCs with unenhanced HU >10 and available washout, 10 (34.4%) 222 
had a high APW and/or RPW.  223 
  224 
Discussion 225 
We retrospectively evaluated the CT characteristics of PCC in the largest international cohort to 226 
date. Our main goal was to determine the prevalence of PCCs with an ACA-like appearance based 227 
on either a low unenhanced attenuation or a high contrast washout. The analysis was based on 228 
locally generated radiological reports. Unenhanced HU values were available for 376 out of 548 229 
histologically confirmed PCCs, two of which (0,5%) exhibited an attenuation of exactly 10 HU, 230 
consistent with an ACA-like attenuation according to recent ESE/ENS@T guidelines. In addition, 231 
among 76 PCCs with unenhanced HU >10 and available washout, 22 (28,9%) showed a high 232 
APW and/or RPW, wrongfully suggestive of ACA.   233 
In 2016 ESE/ENSAT provided clinical practice guidelines for the management of patients 234 
affected by AIs. It was recommended that, as part of the endocrine workup, PCC should be 235 
excluded by measurement of plasma free or 24h urinary fractionated metanephrines in all AIs. 236 
However, it was discussed that an exception could be made for those cases where a non-237 
contrast-enhanced CT attenuation was ≤10 HU. A disclaimer was made that the evidence to 238 
support this exception was very low, referring to two studies that showed a low likelihood of a 239 
PCC among adrenal lesions that are radiologically suggestive of ACA 16,17. Sane et al. 16 examined 240 
whether PCC could be ruled out as cause of AIs on the basis of unenhanced attenuation values 241 
only. A cohort of 174 patients with AI was evaluated retrospectively. Unenhanced attenuation 242 
was available for 115 tumors. Nine patients had a PCC and in none of these tumors the 243 
unenhanced HU was below 10. They concluded that routine measurements of metanephrines is 244 
unnecessary in an asymptomatic patient with AI, provided that the lesion is of low attenuation, 245 
small and homogenous.  Schalin-Jantti et al. 17 performed a 5-year prospective follow-up study of 246 
56 patients with 69 lipid-rich (i.e. low attenuation) AIs, showing that 24h urinary metanephrines 247 
were normal at baseline as well as during follow-up. In addition, Jun et al. 19 studied 251 patients 248 
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with AI and had similar results, leading to the conclusion that for small lesions (AI size <3 cm) 249 
non-contrast CT can substitute for biochemical testing for PCC. Nevertheless, all of the 250 
conclusions and recommendations made in these previous studies are based on small subsets of 251 
PCCs among cohorts of patients with AIs.  252 
Rather than taking AI as a starting point, in the present study and in one previous report, 253 
primarily patients with PCC were selected. Buitenwerf et al.20 recently conducted a retrospective 254 
study including 214 patients affected by 222 histologically proven PCCs. Two expert radiologists 255 
re-evaluated the CT scans images independently. Only one PCC out of 222 demonstrated an 256 
attenuation value of <10 HU. This was a rare case of ACTH-dependent Cushing disease caused by 257 
a PCC. In the current study we found a similarly low prevalence (0,5%) of PCCs with an  258 
unenhanced attenuation of ≤10 HU. In fact none of the PCCs unenhanced attenuation was below 259 
10 HU and in only two PCCs it was exactly 10 HU. In these two cases, histology possibly provided 260 
some explanation. Hemorrhage, necrosis and additional adrenocortical 23 changes may result in 261 
intralesional heterogeneity, emphasizing the importance of selecting the proper region of 262 
interest for the assessment of attenuation.  263 
 In ~70% of AIs attenuation values are ≤10 HU, illustrating the large number of patients that 264 
might benefit from implementing radiological selection to determine in which patients 265 
biochemical screening is needed as second line test to rule out PCC 24. Based on our results, 266 
assuming a 7% prevalence of PCC among AIs, approximately 2900 patients with AI and an 267 
attenuation value ≤10 HU would need to be biochemically screened in order to diagnose one 268 
PCC. In our opinion, this observation justifies omitting biochemical screening in low-attenuation 269 
AIs in order to prevent unnecessary costs and false-positive test results.  270 
Besides unenhanced HU, contrast washout rates are routinely used for the evaluation of adrenal 271 
lesions. The majority of ACA with an unenhanced HU >10 exhibit a high washout. Conversely, a 272 
high washout does not rule out PCC. We found that in almost one third of PCCs with available 273 
APW/RPW data, washout was high. This is in line with a previously meta-analysis of ten studies 274 
by Woo et al., 25. They reported a rate of PCCs with a high washout pattern of 35%. Washout data 275 
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for AI should therefore not be used to determine whether biochemical testing should be done or 276 
not.  277 
There are several limitations to this study. This is a retrospective study of locally generated 278 
radiology reports coming from different centers using different CT machines, settings and 279 
contrast protocols. Many cases were excluded because of the availability of post-contrast CT 280 
scans only. In addition, drawing of the region of interest for the calculation of radiodensity was 281 
done at the discretion of the local radiologist. The detail to which different quantitative 282 
parameters were reported varied considerably, leading to many missing data. On the other hand, 283 
the data were extracted directly from clinical practice, representative for ‘real life’.    284 
 285 
Conclusion 286 
Based on the lack of PCCs with an unenhanced attenuation of <10 HU, and the low proportion 287 
(0,5%) of PCCs with an attenuation of =10 HU, it seems reasonable to abstain from biochemical 288 
testing for PCC in AIs with an unenhanced attenuation ≤10 HU. The assessment of contrast 289 
washout, however, is unreliable to rule out PCC. 290 
 291 
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Table 1: Characteristics of patients of whom quantitative CT characteristics were available 388 
n=368    
Sex: male (%)  163 (44,2%)  
Age at diagnosis: mean±SD (y)  54,01± 15,05  
Biochemical phenotype: n (%)  
 
Adrenergic  200 (54,3%)  
Noradrenergic  111 (30,1%)  
Normal values  18 (4,8%)  
Unknown  39 (10,5%)  
Hereditary syndrome: n (%)  60 (16,3%) * 
  
* RET (n=32), VHL (n=11), NF1 (n=11), SDHB (n=2), SDHD (n=2), MAX (n=1) and SDHAF2 (n=1) 389 
 390 
 391 
 392 
 393 
 394 
 395 
 396 
 397 
 398 
 399 
 400 
 401 
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Table 2: CT protocols and availability of quantitative data from radiological reports for PCCs 402 
 403 
 
  
CT scan protocol, nr (%) 
 
Unenhanced  
Unenhanced and 
post-contrast  
Contrast washout Unknown  
   
94 (17,2) 117 (21,4)  148 (27,0)  189 (34,5)  
A
v
a
il
a
b
il
it
y
 o
f 
q
u
a
n
ti
ta
ti
v
e
 d
a
ta
, n
 (
%
) Unenhanced HU 
only 
298 (54,4) 55 (58,5) 40 (34,2) 24 (16,2) 179 (94,7)  
Unenhanced HU 
and APW/RPW 
78 (14,2)     77 (52,0) 1 (0,5) 
APW/RPW only 6 (1,1)     6 (4,1)   
None 166 (30,3) 39 (41,5) 77 (65,8) 41(27,7) 9 (4,8) 
 404 
HU, Hounsfield Units; AWP, absolute percentage washout; RWP, relative percentage washout  405 
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Figure 1: CT characteristics of PCCs  406 
 407 
NA, not available; high washout, absolute ≥60% and/or relative ≥40%; low washout, absolute <60% and/or relative <40%.  408 
 409 
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Supplemental data  410 
Supplemental Table 1: CT characteristics of 25 PCCs ACA-like based on unenhanced HU and washout 411 
HU, Hounsfield Units; AWP, absolute percentage washout; RWP, relative percentage washout 412 
Table Click here to download Table Canu_Table1.tif 
Table Click here to download Table Canu_Table2.tif 
Figure Click here to download Figure Canu_Fig1.tif 
